Clinical Trial Update: Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating vorinostat and rituximab in indolent non-Hodgkin lymphoma completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Vorinostat (vorinostat)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-07-06